• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NUS

    Nu Skin Enterprises Inc.

    Subscribe to $NUS
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises, Inc. develops and distributes personal care and wellness products worldwide. It provides skin care systems, including ageLOC Me customized skin care and ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products comprising botanical ingredients derived from renewable sources, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, and LifePak nutritional supplements, as well as other anti-aging nutritional solutions and weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

    IPO Year: 1996

    Exchange: NYSE

    Website: nuskin.com

    Recent Analyst Ratings for Nu Skin Enterprises Inc.

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    See more ratings

    Nu Skin Enterprises Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nu Skin downgraded by Jefferies with a new price target

      Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

      1/31/23 6:17:27 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

      DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

      2/17/22 4:46:52 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

      Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

      11/24/21 11:03:39 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

      DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $47.00 from $61.00 previously

      10/6/21 4:44:14 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises downgraded by DA Davidson with a new price target

      DA Davidson downgraded Nu Skin Enterprises from Buy to Neutral and set a new price target of $58.00 from $71.00 previously

      2/12/21 11:21:17 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises downgraded by DA Davidson

      DA Davidson downgraded Nu Skin Enterprises from Buy to Neutral

      2/12/21 8:21:42 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Jefferies Financial Group reiterated coverage on Nu Skin Enterprises with a new price target

      Jefferies Financial Group reiterated coverage of Nu Skin Enterprises with a rating of Buy and set a new price target of $66.00 from $60.00 previously

      2/2/21 8:02:05 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    Nu Skin Enterprises Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Nu Skin Enterprises Inc.

      10-Q - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      5/8/25 8:52:03 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      5/8/25 4:16:05 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Nu Skin Enterprises Inc.

      SCHEDULE 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      4/17/25 9:35:30 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form DEFA14A filed by Nu Skin Enterprises Inc.

      DEFA14A - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      4/4/25 4:15:18 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form DEF 14A filed by Nu Skin Enterprises Inc.

      DEF 14A - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      4/4/25 4:06:07 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update

      8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      3/6/25 6:04:57 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-K filed by Nu Skin Enterprises Inc.

      10-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      2/14/25 5:23:38 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      2/13/25 4:21:31 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Nu Skin Enterprises Inc.

      SCHEDULE 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      1/31/25 9:56:00 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      1/13/25 7:01:11 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    Nu Skin Enterprises Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue at the high end of its guidance range. Executive Summary Q1 2025 vs. Prior-year Quarter Revenue $364.5 million; (12.7)% (3.0)% FX impact or $(12.3) million Earnings Per Share (EPS) $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges Customers 776,712; (11)% Paid Affiliates 131,518; (15)% Sales Leaders 31,036; (20)% "We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year," said Ryan Napierski, Nu Skin president and CEO. "We drove

      5/8/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 11, 2025, to shareholders of record on May 30, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which

      5/8/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises to Announce First Quarter 2025 Financial Results

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release first quarter 2025 results after the market closes on Thursday, May 8. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, May 22. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of

      4/2/25 4:15:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Reports Fourth Quarter and Full-year 2024 Results Above Company Revenue Guidance

      Company provides initial outlook for Q1 and FY 2025 Nu Skin Enterprises Inc. (NYSE:NUS) today announced fourth quarter and full-year 2024 results above its latest revenue guidance. Executive Summary Q4 2024 vs. Prior-year Quarter Revenue $445.6 million; (8.8)% (4.1)% FX impact or $(20.1) million Rhyz revenue $83.1 million; 27.7% Earnings Per Share (EPS) $(0.73) or $0.38 excluding restructuring and other charges, compared to $0.15 or $0.37 excluding restructuring and other charges Customers 831,972; (15)% Paid Affiliates 144,874; (13)% or (12)% excluding an adjustment to eligibility requirements Sales Leaders 36,91

      2/13/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on March 5, 2025, to shareholders of record on Feb. 24, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, wh

      2/13/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Q4 Preliminary Revenue at High End of Guidance

      Company to discuss performance, strategy and opportunities at ICR Conference; full financial results to be announced Feb. 13 Nu Skin Enterprises Inc. (NYSE:NUS) today announced Q4 2024 preliminary revenue at the high end of the company's guidance range ahead of its presentation at the ICR Conference on Tuesday, Jan. 14. President and CEO Ryan Napierski and CFO James Thomas will participate in a moderated fireside chat to discuss company strategy and the state of the business, including the recent strategic transaction of Mavely for $250 million. The company's presentation will be webcast live beginning at 3 p.m. ET. Those wishing to access the event can visit the Nu Skin investor relati

      1/13/25 7:00:00 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Later Acquires Mavely for $250 Million, Unlocking New Opportunities for Marketers and Creators to Maximize their Return on Social

      BOSTON, Jan. 3, 2025 /PRNewswire/ -- Later, a leader in influencer marketing and social media management software and services, today announced its acquisition of Mavely, the leading Everyday Influencer Platform.® This acquisition accelerates Later's ability to deliver full-funnel impact and measurable ROI for marketers while enabling creators to maximize their earnings through social commerce. The deal, valued at $250 million, was funded with a strategic investment from global growth equity investor, Summit Partners. Later's acquisition of Mavely from Rhyz Inc, a subsidiary o

      1/3/25 6:00:00 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Strategic Transaction of Mavely for $250 Million

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced that its Rhyz Inc. subsidiary completed a strategic transaction with Later, a portfolio company of Summit Partners. As part of the transaction, Rhyz sold its Mavely affiliate marketing technology platform to Later in exchange for approximately $250 million in the form of cash and a minority equity stake in the combined Later/Mavely business. Approximately $33 million of such consideration will be paid to other equity holders in the Mavely business. In connection with the transaction, Mavely is expected to continue to provide certain technology and social commerce capabilities to support Nu Skin's affiliate marketing business. "Together,

      1/3/25 6:00:00 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Reports Third Quarter Results

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced third quarter results in line with guidance. Executive Summary Q3 2024 vs. Prior-year Quarter Revenue $430.1 million; (13.8)% (3.4)% FX impact or $(16.7) million Rhyz revenue $73.1 million; 20.9% Earnings Per Share (EPS) $0.17 compared to $(0.74) or $0.56 excluding an inventory write-off Customers 831,768; (15)% Paid Affiliates 149,264; (20)% or (11)% excluding an adjustment to eligibility requirements Sales Leaders 38,284; (19)% "During the third quarter, we achieved results within our previous guidance range with challenges in the core business partially offset by continued strong growth i

      11/7/24 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Dec. 11, 2024, to shareholders of record on Nov. 29, 2024. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, whic

      11/7/24 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    Nu Skin Enterprises Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/12/24 4:47:17 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/6/24 10:20:59 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/4/24 10:21:31 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      10/18/24 9:40:59 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Nu Skin Enterprises Inc. (Amendment)

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      2/13/24 5:09:51 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Nu Skin Enterprises Inc.

      SC 13G - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      2/9/24 12:18:32 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Nu Skin Enterprises Inc. (Amendment)

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      2/8/24 10:14:32 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Nu Skin Enterprises Inc. (Amendment)

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      1/25/24 11:05:44 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Nu Skin Enterprises Inc. (Amendment)

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      8/9/23 3:50:09 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Nu Skin Enterprises Inc. (Amendment)

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      2/13/23 12:56:58 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    Nu Skin Enterprises Inc. Financials

    Live finance-specific insights

    See more
    • Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue at the high end of its guidance range. Executive Summary Q1 2025 vs. Prior-year Quarter Revenue $364.5 million; (12.7)% (3.0)% FX impact or $(12.3) million Earnings Per Share (EPS) $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges Customers 776,712; (11)% Paid Affiliates 131,518; (15)% Sales Leaders 31,036; (20)% "We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year," said Ryan Napierski, Nu Skin president and CEO. "We drove

      5/8/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 11, 2025, to shareholders of record on May 30, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which

      5/8/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises to Announce First Quarter 2025 Financial Results

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release first quarter 2025 results after the market closes on Thursday, May 8. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, May 22. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of

      4/2/25 4:15:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Reports Fourth Quarter and Full-year 2024 Results Above Company Revenue Guidance

      Company provides initial outlook for Q1 and FY 2025 Nu Skin Enterprises Inc. (NYSE:NUS) today announced fourth quarter and full-year 2024 results above its latest revenue guidance. Executive Summary Q4 2024 vs. Prior-year Quarter Revenue $445.6 million; (8.8)% (4.1)% FX impact or $(20.1) million Rhyz revenue $83.1 million; 27.7% Earnings Per Share (EPS) $(0.73) or $0.38 excluding restructuring and other charges, compared to $0.15 or $0.37 excluding restructuring and other charges Customers 831,972; (15)% Paid Affiliates 144,874; (13)% or (12)% excluding an adjustment to eligibility requirements Sales Leaders 36,91

      2/13/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on March 5, 2025, to shareholders of record on Feb. 24, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, wh

      2/13/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Q4 Preliminary Revenue at High End of Guidance

      Company to discuss performance, strategy and opportunities at ICR Conference; full financial results to be announced Feb. 13 Nu Skin Enterprises Inc. (NYSE:NUS) today announced Q4 2024 preliminary revenue at the high end of the company's guidance range ahead of its presentation at the ICR Conference on Tuesday, Jan. 14. President and CEO Ryan Napierski and CFO James Thomas will participate in a moderated fireside chat to discuss company strategy and the state of the business, including the recent strategic transaction of Mavely for $250 million. The company's presentation will be webcast live beginning at 3 p.m. ET. Those wishing to access the event can visit the Nu Skin investor relati

      1/13/25 7:00:00 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Later Acquires Mavely for $250 Million, Unlocking New Opportunities for Marketers and Creators to Maximize their Return on Social

      BOSTON, Jan. 3, 2025 /PRNewswire/ -- Later, a leader in influencer marketing and social media management software and services, today announced its acquisition of Mavely, the leading Everyday Influencer Platform.® This acquisition accelerates Later's ability to deliver full-funnel impact and measurable ROI for marketers while enabling creators to maximize their earnings through social commerce. The deal, valued at $250 million, was funded with a strategic investment from global growth equity investor, Summit Partners. Later's acquisition of Mavely from Rhyz Inc, a subsidiary o

      1/3/25 6:00:00 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Reports Third Quarter Results

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced third quarter results in line with guidance. Executive Summary Q3 2024 vs. Prior-year Quarter Revenue $430.1 million; (13.8)% (3.4)% FX impact or $(16.7) million Rhyz revenue $73.1 million; 20.9% Earnings Per Share (EPS) $0.17 compared to $(0.74) or $0.56 excluding an inventory write-off Customers 831,768; (15)% Paid Affiliates 149,264; (20)% or (11)% excluding an adjustment to eligibility requirements Sales Leaders 38,284; (19)% "During the third quarter, we achieved results within our previous guidance range with challenges in the core business partially offset by continued strong growth i

      11/7/24 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Dec. 11, 2024, to shareholders of record on Nov. 29, 2024. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, whic

      11/7/24 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises to Announce Third Quarter 2024 Financial Results

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release third quarter 2024 results after the market closes on Thursday, Nov. 7. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, Nov. 21. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family

      10/7/24 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    Nu Skin Enterprises Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, President of Global Sales Keisel Justin S increased direct ownership by 0.19% to 90,922 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      3/24/25 6:06:31 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Director Woodbury Edwina D was granted 12 shares, increasing direct ownership by 0.04% to 29,471 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      3/6/25 7:27:39 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • EVP, President of Global Sales Keisel Justin S was granted 51,747 shares, increasing direct ownership by 133% to 90,749 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      2/27/25 4:48:55 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Chief Product Officer Hatchett Steven Keith was granted 64,684 shares, increasing direct ownership by 71% to 155,565 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      2/27/25 4:47:07 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • EVP and General Counsel Clark Chayce David was granted 113,196 shares, increasing direct ownership by 81% to 253,345 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      2/27/25 4:44:47 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Chief Financial Officer Thomas James D was granted 71,152 shares, increasing direct ownership by 109% to 136,355 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      2/27/25 4:42:49 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • President and CEO Napierski Ryan S was granted 310,479 shares, increasing direct ownership by 93% to 643,433 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      2/27/25 4:40:56 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Director Battle Emma S. sold $13,087 worth of shares (1,693 units at $7.73), decreasing direct ownership by 9% to 17,530 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      2/24/25 4:39:36 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • EVP, President of Global Sales Keisel Justin S covered exercise/tax liability with 5,552 shares, decreasing direct ownership by 12% to 39,002 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      2/19/25 5:36:19 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Chief Product Officer Hatchett Steven Keith covered exercise/tax liability with 8,949 shares, decreasing direct ownership by 9% to 90,881 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      2/19/25 5:34:13 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    Nu Skin Enterprises Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Nu Skin Enterprises Appoints Mark A. Zorko to Board of Directors

      Nu Skin Enterprises (NYSE:NUS) today announced the appointment of Mark A. Zorko, a principal with executive management association Brentwood Advisory Group, to the company's board of directors. The board also appointed Zorko to serve on its audit committee and the nominating and corporate governance committee. "Mark brings extensive C-level leadership experience with several global public companies, as well as more than 20 years of board-level experience," said Steven J. Lund, executive chairman of the board. "We welcome Mark to the board and look forward to leveraging his extensive business insights and experience." Zorko is a principal with Brentwood Advisory, an association he co-found

      9/12/24 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nu Skin Sets New GUINNESS WORLD RECORDS™ Title for the Most People Packing Meal Kits in 24 Hours

      To celebrate the company's 40th anniversary, sales leaders, employees and local partners packed more than 550,000 meals for children throughout the United States Nu Skin Enterprises, Inc. (NYSE:NUS), a global leader in beauty and wellness, today announced a new GUINNESS WORLD RECORDS title for the Most People Packing Meal Kits in 24 Hours. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729413403/en/Nu Skin Sets New GUINNESS WORLD RECORDS™ Title for the Most People Packing Meal Kits in 24 Hours (Graphic: Business Wire) Nu Skin hosted a service event at the Salt Palace Convention Center in Salt Lake City where 2,196 people ac

      7/29/24 8:00:00 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Helo Corp Welcomes Kevin Fuller as President of Helo AI

      SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2023 / Helo Corp. (OTC:HLOC) ("Helo" or the "Company") is pleased to announce that Kevin Fuller has joined its executive team as president of Helo AI and chief marketing officer of Helo, effective December 1, 2023."We are delighted to welcome Kevin to our executive team," said Seán McVeigh, Helo's chief executive officer. "Kevin brings significant product development and marketing experience, arising from his previous roles as a senior executive with other leading technology and wellness companies. His passion and leadership add to the significant momentum of our Helo AI platform and upcoming products."Mr. Fuller, 53, served as cofounder and chie

      12/12/23 8:30:00 AM ET
      $NUS
      $USNA
      Other Pharmaceuticals
      Health Care
      Medicinal Chemicals and Botanical Products
    • Nu Skin Enterprises Appoints James D. Thomas as Chief Financial Officer

      PROVO, Utah, July 27, 2023 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of James D. Thomas as executive vice president and chief financial officer. Thomas has been serving as interim CFO for the past four months and has been the company's chief accounting officer for the past four years. "Based on his extensive experience, James has a deep understanding of our operations and the ability to strategically align our financial resources to support our current business as well as our vision for the future," said Ryan Napierski, president and

      7/27/23 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Appoints Transformational Beauty Industry Executive Connie Tang to Lead Global Growth and Customer Experience

      PROVO, Utah, April 21, 2021 /PRNewswire/ -- Nu Skin, a global leader in innovative beauty and wellness products powered by its dynamic business opportunity platform, today announced Connie Tang has joined the company as executive vice president and chief global growth & customer experience officer. Tang has established herself as a top business leader with a track record of guiding global organizations through effective transformations to become more customer centered, digitally agile and better equipped to flourish in today's evolving economy. In this role, Tang will oversee

      4/21/21 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces CEO Transition Plan

      PROVO, Utah, Feb. 10, 2021 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced Ryan Napierski, the company's president, has been selected by the Nu Skin Board of Directors to become the company's next president and chief executive officer. Napierski will succeed Nu Skin CEO Ritch Wood, who has decided to retire as CEO effective Sept. 1, 2021, after a successful 30-year career with the company. Wood will continue as an executive advisor through early 2022, and it is anticipated that Napierski will assume Wood's position on the Board at the 2021 stockholder meeting in June. Wood, who served as Nu Skin's chief financial officer for 14 years before becoming CEO in 2017, has

      2/10/21 8:01:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care